Hormonal
GLP1R gene polymorphisms (specifically rs10305420 and rs6923761) significantly predict differential weight loss responses to GLP-1 receptor agonists like liraglutide, with certain variants linked to poor anti-obesity response.
If you are struggling to lose weight on GLP-1 medications like liraglutide despite strict adherence, ask your doctor about pharmacogenetic testing for GLP1R variants. Your genetic makeup may dictate whether this specific drug is the right fit for you, helping you avoid ineffective treatments and switch to alternatives sooner.
The GLP1R rs10305420 polymorphism was linked to a poor anti-obesity response to liraglutide (p = 0.025). On the other hand, carriers of at least one rs6923761 minor allele showed a tendency toward greater weight loss (p = 0.058).
Why this rating
Based on specific cohort studies (Polish, Chinese, PCOS) cited in the review, showing statistically significant associations.
Source
Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
Michał Nicze et al. · International Journal of Molecular Sciences · 2026
DOI 10.3390/ijms27062539
More from this paper
- The presence of anti-drug antibodies (ADAs) to GLP-1 receptor agonists does not necessarily neutralize their clinical efficacy, although it may increase the risk of hypersensitivity reactions.Good
- Phenotype-guided treatment selection (matching drug mechanism to obesity subtype like 'hungry brain' or 'slow burn') results in significantly greater weight loss compared to standard care.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →